ClinicalTrials.gg
TerminatedNCT03448978Updated Jul 1, 2024

Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma

A Phase 1 interventional study of Descartes-08 and Fludarabine in Multiple Myeloma, sponsored by Cartesian Therapeutics. Terminated at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-01.

Sponsored by Cartesian Therapeutics · Phase 1, Interventional, and Treatment

Why this study was terminated
Phase 1 enrollment completed. Further clinical development terminated

From the registry’s dates

  • Primary completion was Apr 2021, 5 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 110 studies testing fludarabine in Multiple Myeloma — 5 open to participants now, 12 under way, none of them phase 3. fludarabine · Multiple Myeloma.

Enrollment
51st of 109
32 · median 31
Started
2018
with 4 others
Phase 1
32 of 110
1 open now
Registered
90th of 110
by date

Among the 110 studies testing fludarabine in Multiple Myeloma, this one is the 51st largest by enrollment of the 109 interventional ones that give a count, is one of 5 that started in 2018, is one of 32 in phase 1, and was the 90th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

5 of the 110 studies testing fludarabine in Multiple Myeloma are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About fludarabine

fludarabine: first FDA approval 1991 (FLUDARA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 584 Multiple Myeloma studies recruiting now, 429 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing fludarabine in Multiple Myeloma, or all of them as a file.
02

Study summary

This Phase I study will test the safety and anti-myeloma activity of ascending doses of Descartes-08 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible patients with active multiple myeloma.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Descartes-08
  • CAR T Cell
  • CART
  • CAR-T
  • CAR T-Cell
  • Multiple Myeloma
  • BCMA
  • B-cell maturation antigen
  • B cell maturation antigen
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Multiple myeloma that is double- to a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD) after at least 2 OR have failed at least 3 prior lines of therapy
  • activity as indicated by serum or urine M-protein, serum free light chain, -proven plasmacytoma, >5% bone marrow plasma cells.
  • Adequate vital organ function as indicated by (>1000/uL), count (>50,000/uL), (>8 g/dL), serum and AST (each \<3.0 x ), total (\<2 mg/dL), (>30 mL/min), and cardiac (>45%)

Exclusion criteria

Exclusion Criteria (condensed):

NOTE: Prior anti-BCMA or CAR-T therapy is NOT exclusionary

  • Active plasma cell leukemia
  • Pregnant or lactating
  • Active, uncontrolled infection
  • Active and severe auto-immune disease
  • Active arrhythmia, or obstructive or restrictive pulmonary disease
  • Central nervous system disease
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Descartes-08 plus fludarabine/cyclophosphamide pretreat

    Autologous CD8+ T-cells transiently expressing an anti-BCMA chimeric antigen receptor

    Biological: Descartes-08 · Drug: Fludarabine · Drug: Cyclophosphamide

Interventions

  • BiologicalDescartes-08

    autologous CD8+ T-cells transiently expressing an anti-BCMA chimeric antigen receptor

    Also known as: CAR-T cells

  • intravenous fludarabine

  • intravenous cyclophosphamide

06

What researchers measure

Primary outcomes

  1. Incidence (number) of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Incidence (number) of Treatment-Emergent Adverse Events \[Safety and Tolerability\]. Descriptive statistics by incidence rate, body system classification, severity, and causality \[per protocol definitions\]

    Time frame: 2 weeks

Secondary outcomes

  1. Treatment response

    IMWG treatment response criteria

    Time frame: 1, 3, 6, 9 and 12 months

07

Study locations

3 sites
  • The Center for Cancer and Blood Disorders
    Bethesda, Maryland 20817, United States
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
  • Virgina Cancer Specialists
    Fairfax, Virginia 22031, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2018 to primary completion in Apr 2021, 37 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2018
First posted
Feb 28, 2018
StartActual
Mar 8, 2018
Primary completionActual
Apr 19, 2021
CompletionActual
Jun 3, 2021
Last update
Jul 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03448978
Lead sponsor
Cartesian Therapeutics
Responsible party
Sponsor
First posted
Feb 28, 2018
Start date
Mar 8, 2018
Primary completion
Apr 19, 2021
Completion
Jun 3, 2021
Last update
Jul 1, 2024

Study contacts

Metin Kurtoglu, MD, PhD
study director · Cartesian Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytes · Fludarabine · Cyclophosphamide

Start the discussion